UroLift System with Stereotactic Ablative Body Radiotherapy for the Treatment of Prostate Cancer and Benign Prostatic Hyperplasia
This phase I trial evaluates the safety of the UroLift System and stereotactic ablative body radiotherapy in treating patients with prostate cancer and benign prostatic hyperplasia. A newer generation radiation therapy called, stereotactic ablative body radiotherapy, is a highly effective radiation therapy for patients with prostate cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. However, patients with enlarged prostate or benign prostatic hyperplasia (BPH), who also have lower urinary tract symptoms are often excluded from this prostate cancer therapy because radiation may worsen existing urinary symptoms. UroLift system, a procedure that lifts or holds enlarged prostate tissue out of the way so it no longer blocks the urethra. This study may help researchers determine if the UroLift System together with stereotactic body radiotherapy can be safely performed in men with BPH and prostate cancer.